ETFs Akeso, Inc.

9926

KYG0146B1032

Biotechnology & Medical Research

Market Closed - Hong Kong S.E. Other stock markets 01:38:46 08/07/2025 pm IST			5-day change	1st Jan Change
109.80 ^HKD	-2.83%		+18.32%	+80.89%

03/07	Summit, AstraZeneca in talks over $15 billion cancer drug licensing deal, Bloomberg News reports	RE
03/07	Akeso's First Bispecific Adc (Trop2/Nectin4 Adc) Enters Clinical Trials, Strengthening Leadership in 'Io+Adc'2.0 Strategy	CI

ETFs positioned on Akeso, Inc.

Name	Weight	AuM	1st Jan change
LEADERSHARES EQUITY SKEW ETF - USD	0.03%	89 M€	-1.30%	-
DAY HAGAN/NED DAVIS RESEARCH SMART SECTOR INTERNATIONAL ETF - USD	0.01%	32 M€	+13.69%	-
VANGUARD INTERNATIONAL EQUITY INDEX FUNDS - VANGUARD FTSE ALL-WORLD EX-US ETF	0.01%	33,076 M€	+11.74%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF ACC - EUR	0%	619 M€	-1.87%	-
DEMOCRACY INTERNATIONAL FUND ETF - USD	0%	9 M€	+14.35%	-
VANGUARD LIFESTRATEGY 80% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	53 M€	-2.29%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	61 M€	-1.47%	-
VANGUARD LIFESTRATEGY 60% EQUITY UCITS ETF - ACC - EUR	0%	467 M€	-0.59%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF ACC - EUR	0%	139 M€	+0.30%	-
VANGUARD LIFESTRATEGY 40% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	28 M€	-0.98%	-
NOMURA NEXT FUNDS EMERGING MARKET EQUITY MSCI-EM (UNHEDGED) ETF - JPY	0%	17 M€	+7.00%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF ACC - EUR	0%	68 M€	+0.98%	-
VANGUARD LIFESTRATEGY 20% EQUITY UCITS ETF - DISTRIBUTING - EUR	0%	10 M€	-0.52%	-

Akeso Inc is an investment holding company mainly engaged in the research and development, production and commercialization of biopharmaceutical products. The Company is committed to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The Company's products mainly include cadonilimab (PD-1/CTLA-4), Ivonescimab (AK112, PD-1/VEGF), ANNIKO (penpulimab, PD-1), Ebronucimab (AK102, PCSK9) and ebdarokimab (AK101, IL-12/IL-23). The Company's products are principally used to treat tumors, autoimmune diseases, metabolic diseases, as well as neurodegenerative diseases. The Company principally conducts its businesses in Mainland China, the United States and other markets.

Employees

3,035

Sector

Biotechnology & Medical Research

Calendar

27/08 - Q2 2025 Earnings Release (Projected)

More about the company